Diurnal Group PLC Posting of Annual Report and AGM Notice (5503B)
09 October 2020 - 12:28AM
UK Regulatory
TIDMDNL
RNS Number : 5503B
Diurnal Group PLC
08 October 2020
8 October 2020
Diurnal Group plc
("Diurnal" or the "Company")
Posting of Annual Report and AGM Notice
Diurnal Group plc (AIM: DNL), the specialty pharmaceutical
company targeting patient needs in chronic endocrine (hormonal)
diseases, announces that its Annual Report and Accounts for the
year ending 30 June 2020, together with the Notice of Annual
General Meeting (AGM), have today been posted to shareholders.
The documents are being made available on the investor relations
section of the Company's website, www.diurnal.co.uk .
The Company's AGM will be held at 11:00 GMT at the Company's
London office at Regus Woburn Place, 16 Upper Woburn Place, London,
WC1H 0BS on Tuesday 20 November 2020. Due to the ongoing COVID-19
pandemic and in line with UK Government advice, the Board has
decided to run the 2020 AGM as a closed meeting and shareholders
will not be able to attend.
In the light of these measures, the Board strongly encourages
shareholders to vote by proxy in accordance with the instructions
in the Notice of AGM. Shareholders can submit questions to the
Company ahead of the AGM as per instructions included within the
Notice of AGM.
For further information, please visit www.diurnal.co.uk or
contact:
+44 (0)20 3727
Diurnal Group plc 1000
Martin Whitaker, Chief Executive Officer
Richard Bungay, Chief Financial Officer
Panmure Gordon (UK) Limited (Nominated Adviser +44 (0)20 7886
and Sole Broker) 2500
Corporate Finance: Freddy Crossley, Emma Earl
Corporate Broking: Rupert Dearden
+44 (0)20 3727
FTI Consulting (Media and Investor Relations) 1000
Simon Conway
Victoria Foster Mitchell
Notes to Editors
About Diurnal Group plc
Founded in 2004, Diurnal is a UK-headquartered, European
specialty pharma company developing high quality products for the
global market for the life-long treatment of chronic endocrine
conditions, including congenital adrenal hyperplasia and adrenal
insufficiency. Its expertise and innovative research activities
focus on circadian-based endocrinology to yield novel product
candidates in the rare and chronic endocrine disease arena.
For further information about Diurnal, please visit
www.diurnal.co.uk
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NOABXBDGLDGDGGI
(END) Dow Jones Newswires
October 08, 2020 09:28 ET (13:28 GMT)
Diurnal (LSE:DNL)
Historical Stock Chart
From Apr 2024 to May 2024
Diurnal (LSE:DNL)
Historical Stock Chart
From May 2023 to May 2024